After its product was selected earlier this year as one of Time magazine’s 100 best inventions for 2019, Israeli startup Theranica, the developer of a medical device for the treatment of acute migraine, has been chosen by New York data company CB Insights as one of next year’s 36 startup “game changers.”
The firm was ranked in CB Insights’ Game Changers for 2020, in which the US firm identified “high-momentum companies pioneering new ways to solve big problems.”
Theranica was mentioned in the category of “electro-charged therapeutics,” in which treatment of diseases and ailments occurs with electrical impulses instead of chemical drugs.
The Netanya, Israel-based firm developed the Nerivio, a device worn on the upper arm that uses smartphone-controlled electronic pulses to wirelessly stimulate the body’s neural pathway at the onset of a migraine.
Nerivio is a wireless non-invasive remote electrical stimulation wearable applied to the upper arm at the onset of migraine headache or aura.
Nerivio induces an inherent pain inhibition brain mechanism, resulting in a clinically significant pain relief. Nerivio is safe and well-tolerated.
Nerivio is controlled by an easy-to-use app that provides personalized treatments and offers an advanced migraine diary to track treatment sessions and migraine headaches.
The migraine diary can be shared between patients and their healthcare professionals to improve migraine management.
Nerivio is FDA authorized
INDICATION FOR USE
Nerivio is indicated for acute treatment of migraine with or without aura in patients 18 years of age or older who do not have chronic migraine. It is a prescription use, self-administered device for use in the home environment at the onset of migraine headache or aura.
IMPORTANT SAFETY INFORMATION
Nerivio should not be used by people with congestive heart failure, severe cardiac or cerebrovascular disease, or uncontrolled epilepsy.
Nerivio should not be used by anyone with active implantable medical devices (eg, pacemaker, hearing aid implant).
It should only be applied on the upper arm over dry, healthy skin with normal physical sensation and without any metallic implants or in proximity to cancerous lesions. Nerivio has not been evaluated in pregnancy or those under the age of 18
The device is currently available by prescription in the US in some headache and migraine clinics, and will be available in Israel in April, the firm said last month. Nerivio is Theranica’s first FDA authorized medical device.
CB Insights selected 36 global companies across 12 categories, including chips, next generation nuclear energy, mind-altering medicines, AI-based protein prediction firms and gene editing startups, identifying emerging trends to watch and “high momentum companies pioneering technology with the potential to transform society and economies for the better.”
“Migraine is a debilitating disease that demands intervention,” said Alon Ironi, co-founder and CEO of Theranica, in a statement released by the firm regarding its inclusion in the CB Insights list.
“Theranica’s approach to acute treatment of migraine suggests a drug-free option as a first line therapy.
Utilizing the brain’s native conditioned pain modulation response has been shown to offer an affordable, drug-free, non-invasive alternative to drug-based medications,” Ironi said.
Last year, two Israeli firms were selected by CB Insights as game changers: Autotalks, a Kfar Netter-based maker of vehicle-to-vehicle communication systems for use in autonomous driving cars, and Tel Aviv-based AdVerif.ai, an artificial intelligence company that allows advertisers, publishers, and ad networks to moderate content and battle fake news.
CB Insights categories were selected by the firm’s tech market intelligence platform, which uses algorithms to scout through millions of media articles to identify game changing tech trends.
The companies are selected using algorithms that track “company health” including recent financing and investor quality and submissions from firms and professionals.